OraSure Wins FDA Nod for OraQuick Ebola Test

The FDA has allowed marketing of OraSure Technologies’ OraQuick rapid diagnostic test to detect Ebola virus antigens (proteins) in human blood from certain living individuals and samples from certain recently deceased individuals suspected to have died from Ebola.

• OraQuick Ebola Rapid Antigen Test is first rapid diagnostic test FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease
• OSUR shares spiked up 4.1% before settling to a 1.7% gain

Link to Statement

To contact the reporter on this story:
Nick Lichtenberg in New York at nlichtenberg@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli ...